Novartis AG and Pfizer Inc. Compete for a Bigger Share of the Pharmaceuticals Market

LONDON–(BUSINESS WIRE)–#Biotechnology—Technavio’s market research reports examine the competitive landscape and provide detailed insights into the market scenario over the next five years.

The research reports examine the impact of the key players on a global level as well as in specific regions and countries. The reports also provide an overview of the challenges and opportunities in each market to provide actionable insights which will help clients drive business growth.

Novartis AG and Pfizer Inc. are competing for a bigger share of the pharmaceuticals segment, backed by the increasing investments in R&D, constant innovations and new product launches.

Key Highlights from Technavio

Global Orthostatic Hypotension Drugs Market 2019-2023: Request a sample report

• The increasing prevalence of chronic diseases will also contribute to the growth of the orthostatic hypotension (OH) drugs market as orthostatic hypotension is associated with various neurodegenerative diseases, cardiovascular diseases, and conditions such as diabetes.
• North America will account for the highest OH drugs market share throughout the forecast period due to factors such as high per capita pharmaceutical expenditure, strong market presence of leading vendors, access to advanced healthcare, and increasing awareness about OH.
• The Northera (Droxidopa) segment will grow faster and emerge as the market leader by the end of the forecast period as it can activate alpha-1 adrenergic receptors and have numerous physiological effects that may ameliorate the symptoms of nOH.

Global MEK Inhibitors Market 2019-2023: Request a sample report

• The high target affinity and specificity of MEK inhibitors will contribute to the growth of the market as approved therapies for the treatment of advanced or metastatic carcinomas, such as melanoma and NSCLC, have a low patient adherence due to their side effects.
• The MEKINIST segment will account for the highest MEK inhibitors market share. The increasing sale of MEKINIST because of the expansion of research indications focusing on new patient pools will be one of the significant factors driving the growth of the MEK inhibitors market in this segment.
• North America will account for the highest MEK inhibitors market share throughout the forecast period due to the rising prevalence of several cancer indications and the increasing sales of approved MEK inhibitors.

Global Neglected Tropical Disease Treatment Market 2019-2023: Request a sample report

• The initiatives undertaken by several organizations across the world to increase awareness and access to medicines for neglected tropical diseases will drive market growth.
• Poor sanitation facilities in a few African countries have increased the prevalence of neglected tropical diseases that cause disfigurement and long-lasting disabilities. The region is also witnessing the launch of several programs to help reduce the prevalence of neglected tropical diseases.
• Antiparasitic drugs are most commonly used for the treatment of neglected tropical diseases due to the availability, approval, and development of antiparasitic therapeutics to treat neglected tropical diseases.

Technavio has recently published numerous reports on the latest developments in the pharmaceuticals industry. Our continuously growing healthcare catalog provides the latest insights on several industry verticals in addition to the above-listed reports.